GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (STU:J7Z) » Definitions » Cyclically Adjusted FCF per Share

Jazz Pharmaceuticals (STU:J7Z) Cyclically Adjusted FCF per Share : €12.50 (As of Mar. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Jazz Pharmaceuticals Cyclically Adjusted FCF per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Jazz Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2025 was €5.930. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €12.50 for the trailing ten years ended in Mar. 2025.

During the past 12 months, Jazz Pharmaceuticals's average Cyclically Adjusted FCF Growth Rate was 17.50% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 16.90% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was 16.50% per year. During the past 10 years, the average Cyclically Adjusted FCF Growth Rate was 35.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Jazz Pharmaceuticals was 101.70% per year. The lowest was 16.30% per year. And the median was 23.40% per year.

As of today (2025-05-24), Jazz Pharmaceuticals's current stock price is €95.16. Jazz Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 was €12.50. Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is 7.61.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Jazz Pharmaceuticals was 334.41. The lowest was 7.21. And the median was 23.36.


Jazz Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

The historical data trend for Jazz Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Jazz Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.30 7.32 8.85 9.85 12.42

Jazz Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 10.52 11.16 11.13 12.42 12.50

Competitive Comparison of Jazz Pharmaceuticals's Cyclically Adjusted FCF per Share

For the Biotechnology subindustry, Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


;
;

Jazz Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Jazz Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=5.93/123.4051*123.4051
=5.930

Current CPI (Mar. 2025) = 123.4051.

Jazz Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 1.801 100.573 2.210
201509 2.397 100.274 2.950
201512 1.698 99.676 2.102
201603 2.014 99.676 2.493
201606 -0.381 101.072 -0.465
201609 1.667 100.274 2.052
201612 2.787 99.676 3.450
201703 2.460 100.374 3.024
201706 1.809 100.673 2.217
201709 1.441 100.474 1.770
201712 2.592 100.075 3.196
201803 2.124 100.573 2.606
201806 1.069 101.072 1.305
201809 3.014 101.371 3.669
201812 3.099 100.773 3.795
201903 2.107 101.670 2.557
201906 1.652 102.168 1.995
201909 4.235 102.268 5.110
201912 1.268 102.068 1.533
202003 0.855 102.367 1.031
202006 1.221 101.769 1.481
202009 3.692 101.072 4.508
202012 2.101 101.072 2.565
202103 4.069 102.367 4.905
202106 0.482 103.364 0.575
202109 3.438 104.859 4.046
202112 2.414 106.653 2.793
202203 2.478 109.245 2.799
202206 3.305 112.779 3.616
202209 6.803 113.504 7.396
202212 -0.635 115.436 -0.679
202303 3.999 117.609 4.196
202306 3.653 119.662 3.767
202309 3.981 120.749 4.069
202312 1.833 120.749 1.873
202403 3.683 120.990 3.757
202406 4.327 122.318 4.365
202409 5.533 121.594 5.615
202412 5.983 122.439 6.030
202503 5.930 123.405 5.930

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.


Jazz Pharmaceuticals  (STU:J7Z) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Jazz Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=95.16/12.50
=7.61

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Jazz Pharmaceuticals was 334.41. The lowest was 7.21. And the median was 23.36.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Jazz Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Jazz Pharmaceuticals Business Description

Industry
Traded in Other Exchanges
Address
Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals Headlines

No Headlines